Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cetuximab plus platinum/pemetrexed in first-line malignant pleural mesothelioma
2009-014293-17Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in pleural mesothelioma, sponsored by Ghent University Hospital. Primary endpoint: Progression-free survival rate at 18 weeks. Started Jul 2009; status: completed.
02
Drugs
cetuximab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2009-014293-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014293-17.